CEO of Therapeuticsmd Inc (30-Year Financial, Insider Trades) Robert G Finizio (insider trades) bought 46,000 shares of TXMD on 06/09/2020 at an average price of $1.44 a share. The total cost of this purchase was $66,240.
TherapeuticsMD Inc is a women's health care company focused on creating and commercializing products targeted exclusively for women. It is engaged in pre-commercialization activities for advanced hormone therapy pharmaceutical product. TherapeuticsMD Inc has a market cap of $366.780 million; its shares were traded at around $1.35 with and P/S ratio of 5.90. TherapeuticsMD Inc had annual average EBITDA growth of 20.10% over the past ten years. GuruFocus has detected 4 severe warning signs with TherapeuticsMD Inc. .
CEO Recent Trades:
- CEO Robert G Finizio bought 46,000 shares of TXMD stock on 06/09/2020 at the average price of $1.44. The price of the stock has decreased by 6.25% since.
- CEO Robert G Finizio bought 30,000 shares of TXMD stock on 06/05/2020 at the average price of $1.15. The price of the stock has increased by 17.39% since.
Directors and Officers Recent Trades:
- Director Cooper C. Collins bought 74,000 shares of TXMD stock on 06/09/2020 at the average price of $1.45. The price of the stock has decreased by 6.9% since.
- Director Tommy G Thompson bought 8,700 shares of TXMD stock on 06/04/2020 at the average price of $1.13. The price of the stock has increased by 19.47% since.
- Director Paul Bisaro bought 50,000 shares of TXMD stock on 06/04/2020 at the average price of $1.14. The price of the stock has increased by 18.42% since.
For the complete insider trading history of TXMD, click here
.
